Swedish oncology-focused development company Vivesto AB (STO:VIVE) on Thursday reported positive preclinical results for its Cantrixil drug candidate.

The data demonstrated the efficacy of Cantrixil in combination with other anti-cancer drugs in haematological cancer cell lines.

Vivesto has also filed a new patent application to strengthen its intellectual property position for Cantrixil.

The company plans to present additional preclinical data from haematological cancer models throughout 2025. These results will inform the dosing strategy for future clinical trials.